SPC3 synthetic polymer: Filed IND to start Phase I/II U.S. trials to optimize dosage in late-stage seropositive patients. Trials are ongoing in Europe.

Columbia Laboratories Inc. (COB), Miami Product: SPC3 synthetic polymer, intended to block entry of HIV into cells and prevent syncytia formation (fusion of lymphocytes with infected cells) Indication...